Home > Publications database > USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer. > print

001     294136
005     20250123143201.0
024 7 _ |a 10.1038/s41388-024-03141-x
|2 doi
024 7 _ |a pmid:39443725
|2 pmid
024 7 _ |a 0950-9232
|2 ISSN
024 7 _ |a 1476-5594
|2 ISSN
024 7 _ |a altmetric:169629643
|2 altmetric
037 _ _ |a DKFZ-2024-02134
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Reissland, Michaela
|0 0000-0002-4704-9392
|b 0
245 _ _ |a USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer.
260 _ _ |a London
|c 2024
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1737639093_22317
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:A100# / 2024 Dec;43(50):3645-3659
520 _ _ |a The contribution of deubiquitylating enzymes (DUBs) to β-Catenin stabilization in intestinal stem cells and colorectal cancer (CRC) is poorly understood. Here, and by using an unbiassed screen, we discovered that the DUB USP10 stabilizes β-Catenin specifically in APC-truncated CRC in vitro and in vivo. Mechanistic studies, including in vitro binding together with computational modelling, revealed that USP10 binding to β-Catenin is mediated via the unstructured N-terminus of USP10 and is outcompeted by intact APC, favouring β-catenin degradation. However, in APC-truncated cancer cells USP10 binds to β-catenin, increasing its stability which is critical for maintaining an undifferentiated tumour identity. Elimination of USP10 reduces the expression of WNT and stem cell signatures and induces the expression of differentiation genes. Remarkably, silencing of USP10 in murine and patient-derived CRC organoids established that it is essential for NOTUM signalling and the APC super competitor-phenotype, reducing tumorigenic properties of APC-truncated CRC. These findings are clinically relevant as patient-derived organoids are highly dependent on USP10, and abundance of USP10 correlates with poorer prognosis of CRC patients. Our findings reveal, therefore, a role for USP10 in CRC cell identity, stemness, and tumorigenic growth by stabilising β-Catenin, leading to aberrant WNT signalling and degradation resistant tumours. Thus, USP10 emerges as a unique therapeutic target in APC truncated CRC.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Hartmann, Oliver
|b 1
700 1 _ |a Tauch, Saskia
|0 P:(DE-He78)f112986f685bcedfb852b4c86803bece
|b 2
|u dkfz
700 1 _ |a Bugter, Jeroen M
|0 0000-0001-9920-2937
|b 3
700 1 _ |a Prieto-Garcia, Cristian
|b 4
700 1 _ |a Schulte, Clemens
|0 0000-0003-2362-3318
|b 5
700 1 _ |a Loebbert, Sinah
|b 6
700 1 _ |a Solvie, Daniel
|0 0000-0003-4529-667X
|b 7
700 1 _ |a Bitman-Lotan, Eliya
|b 8
700 1 _ |a Narain, Ashwin
|0 0000-0001-5905-3527
|b 9
700 1 _ |a Jacomin, Anne-Claire
|0 0000-0001-8761-1514
|b 10
700 1 _ |a Schuelein-Voelk, Christina
|b 11
700 1 _ |a Fuss, Carmina T
|b 12
700 1 _ |a Pahor, Nikolett
|b 13
700 1 _ |a Ade, Carsten
|0 0000-0001-7226-1179
|b 14
700 1 _ |a Buck, Viktoria
|0 0000-0001-6123-1599
|b 15
700 1 _ |a Potente, Michael
|b 16
700 1 _ |a Li, Vivian
|0 0000-0003-2041-0085
|b 17
700 1 _ |a Beliu, Gerti
|b 18
700 1 _ |a Wiegering, Armin
|0 0000-0001-7777-0909
|b 19
700 1 _ |a Grossmann, Tom
|b 20
700 1 _ |a Eilers, Martin
|0 0000-0002-0376-6533
|b 21
700 1 _ |a Wolf, Elmar
|b 22
700 1 _ |a Maric, Hans
|0 0000-0002-2719-4752
|b 23
700 1 _ |a Rosenfeldt, Mathias
|0 0000-0001-7650-8458
|b 24
700 1 _ |a Maurice, Madelon M
|0 0000-0001-6885-5361
|b 25
700 1 _ |a Dikic, Ivan
|0 0000-0001-8156-9511
|b 26
700 1 _ |a Gallant, Peter
|b 27
700 1 _ |a Orian, Amir
|0 0000-0002-8521-1661
|b 28
700 1 _ |a Diefenbacher, Markus E
|b 29
773 _ _ |a 10.1038/s41388-024-03141-x
|0 PERI:(DE-600)2008404-3
|n 50
|p 3645-3659
|t Oncogene
|v 43
|y 2024
|x 0950-9232
909 C O |p VDB
|o oai:inrepo02.dkfz.de:294136
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)f112986f685bcedfb852b4c86803bece
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOGENE : 2022
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-29
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOGENE : 2022
|d 2023-08-29
920 1 _ |0 I:(DE-He78)A100-20160331
|k A100
|l A100 Signaltransduktion/ Wachstumskontrolle
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A100-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21